compounding glp-1 enforcement news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA to Restrict Ingredients Used

Many insurance plans do not cover these medications, and those that do often require extra steps before approving them

They help maintain muscle mass and ensure satiety

Elevated blood sugar levels can lead to dehydration, and certain diabetes complications, like nerve damage or reduced sweat gland function, can impair the bodys ability to cool down

This matters because beneficiaries may assume that any prescription cost they pay at the pharmacy counts toward their Part D spending

It's also worth thinking about the placebo effect

doi: 10.1097/MIB.0000000000000847 95 KellerJBinnewiesURschMJuul HolstJBeglingerCAndresenVet al